5-methoxycarbonylmethyluridine: tRNA wobble nucleoside; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5-methoxycarbonylmethyluridine : A derivative of uridine, bearing an additional methoxycarbonylmethyl substituent at position 5 on the uracil ring. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 3080753 |
| CHEBI ID | 20598 |
| SCHEMBL ID | 64345 |
| MeSH ID | M0096882 |
| Synonym |
|---|
| 29428-50-0 |
| 5-pyrimidineacetic acid, 1,2,3,4-tetrahydro-2,4-dioxo-1-beta-d-ribofuranosyl-, methyl ester |
| 5-mcmu |
| 5-methoxycarbonylmethyluridine |
| methyl 2-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidin-5-yl]acetate |
| YIZYCHKPHCPKHZ-PNHWDRBUSA-N |
| 5-(methoxycarbonyl)methyluridine |
| methyl uridine 5-acetate |
| CHEBI:20598 |
| 5-(2-methoxy-2-oxoethyl)uridine |
| mcm(5)u |
| uridine 5-acetic acid methyl ester |
| SCHEMBL64345 |
| DTXSID20183642 |
| methyl2-(1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acetate |
| mcm5u |
| methyl 2-(1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)acetate |
| 5-pyrimidineacetic acid, 1,2,3,4-tetrahydro-2,4-dioxo-1-beta-d-ribofur anosyl-, methyl ester |
| F12769 |
| Q27109316 |
| A900280 |
| methyl 2-{1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl}acetate |
| Class | Description |
|---|---|
| uridines | |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.00) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||